Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06389578 · ClinicalTrials.gov registry record · Phase 1
A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06389578 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 16 participants.
The verdict
NCT06389578, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The main goal of this study is to learn how teprotumumab will be processed in the body (Pharmacokinetics) subcutaneously and whether it is safe and tolerable after administration into adult patients with thyroid eye disease.
Interventions
- DRUG Teprotumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2023-09-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06389578
The ClinicalTrials.gov registry entry for NCT06389578 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Teprotumumab is the first listed.
NCT06389578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06389578 about?
NCT06389578 is a clinical study titled "A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease". The main goal of this study is to learn how teprotumumab will be processed in the body (Pharmacokinetics) subcutaneously and whether it is safe and tolerable after administration into adult patients with thyroid eye disease.
What is the current status of trial NCT06389578?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2022-07-14. Estimated completion is 2023-09-12.
What interventions are being tested in trial NCT06389578?
The interventions under investigation include: Teprotumumab (DRUG).
Who is sponsoring clinical trial NCT06389578?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.